CHEMED CORPORATION
In the published model solve dated 2026-Q2, anchored at $523.38, CHEMED CORPORATION (CHE) is priced for +5.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• One operating statistic decides this company: hospice census, and it is still climbing, with the first-quarter 2026 filing showing total average daily census of 22,723 against 22,244 a year earlier and admissions of 19,394 against 18,139. • Nearly all of that revenue comes from a single payer whose rates are set by regulation and capped per admission, and the 10-K warns that rising labor, pharmaceutical and supply costs ⟦without a compensating increase in Medicare and Medicaid rates, could hav
Is CHE overvalued? See what's priced in →
472 institutional managers reported holding CHE in 13F filings for the quarter ended 2026-03-31. Together they hold about 93% of the company; the top 10 hold 41%. 43 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 602k shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (2.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CHE has cut its share count 13.6% over the past five years, spending $1.59B on repurchases. It pays a dividend, and has paid one every year in our records (17 and counting), raised 16 years straight; the current rate is $2.20 a share annually. Cash returned over the past three years: $79.05M in dividends and $1.05B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CHE over the trailing three years: 2024: 1 buy totaling $75k; 2025: 1 buy totaling $83k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CHE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-29 | -8.2% | -0.7% |
| 2023-10-28 | +8.8% | +4.1% |
| 2024-03-01 | +5.0% | -8.7% |
| 2024-04-30 | -7.0% | -4.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CHE's latest 8-K filings: 2026-07-28 (items 2.02, 9.01); 2026-05-19 (items 5.07); 2026-04-23 (items 2.02, 9.01); 2026-04-13 (items 1.01, 2.03, 9.01); 2026-02-25 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.